Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
September 09 2024 - 8:30AM
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical
company focused primarily on treatments for gastrointestinal (GI)
diseases with an emphasis on GIMOTI® (metoclopramide) nasal
spray, announced that management will participate in the
Gastroenterology and Hepatology Advanced Practice Providers
Conference taking place from September 12 – 14, 2024 at the Gaylord
National Resort Convention Center in National Harbor, Maryland.
“As a meeting sponsor for four consecutive years, we are excited
to engage with the advanced practice providers community at the 7th
Annual GHAPP conference, a unique event dedicated to nurse
practitioners and physician assistants who play a pivotal role in
managing patients with gastrointestinal (GI) disorders, including
patients with gastroparesis,” said Matt D’Onofrio, CEO of Evoke
Pharma. “This year, we look forward to discussing GIMOTI and its
positive impact on patients suffering from diabetic
gastroparesis.”
Evoke Pharma’s management and commercial team will host a booth
at the conference to facilitate discussions with attendees.
“My high level of involvement with GI patients allows me to
witness the firsthand challenges of those dealing with
gastroparesis. GIMOTI’s nasal delivery offers a promising new
option that can improve patient outcomes for those suffering from
this disease. My patients benefit from GIMOTI, even if they are
having symptoms, as GIMOTI does not rely on the dysfunctional gut
to work. I continue to observe this with patients being prescribed
GIMOTI in my practice,” Demittre Sorenson PA-C, Center for Advanced
GI, Maitland, FL. “The GHAPP conference is a tremendous opportunity
for advanced practice providers to learn more about innovative
treatments like GIMOTI and to discuss how we can better support
patient needs.“
About GHAPP
The Gastroenterology & Hepatology Advanced Practice
Providers (GHAPP) association is dedicated to developing
educational programs, providing professional advancement services,
and assembling resources for—and guided by—advanced practice
providers (APPs).
The GHAPP conference is the only conference specifically
designed by APPs for the purpose of meeting the educational needs
of APPs who specialize in the management of patients with GI
disorders and chronic liver disease.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on
the development of drugs to treat GI disorders and diseases. The
company developed, commercialized and markets GIMOTI, a nasal spray
formulation of metoclopramide, for the relief of symptoms
associated with acute and recurrent diabetic gastroparesis in
adults.
Diabetic gastroparesis is a GI disorder affecting millions of
patients worldwide, in which the stomach takes too long to empty
its contents resulting in serious GI symptoms as well as other
systemic complications. The gastric delay caused by gastroparesis
can compromise absorption of orally administered medications. Prior
to FDA approval to commercially market GIMOTI, metoclopramide was
only available in oral and injectable formulations and remains the
only drug currently approved in the United States to treat
gastroparesis.
Visit www.EvokePharma.com for more information.
Follow Evoke Pharma on LinkedInFollow Evoke
Pharma on Twitter
Safe Harbor Statement
Evoke cautions you that statements included in this press
release that are not a description of historical facts are
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “will,” “should,
”expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential” or “continue” or the negatives of these terms or other
similar expressions. These statements are based on the company’s
current beliefs and expectations. These forward-looking statements
include statements regarding: guidance regarding 2024 net product
sales; potential future prescribing trends for GIMOTI based on
Evoke’s or EVERSANA’s marketing efforts; Evoke’s commercialization
plans, the potential market opportunity for GIMOTI, Evoke’s
partnership with ASPN Pharmacies, growth in prescriptions, patients
taking GIMOTI and the conversion of prescriptions to fills, and
Evoke’s expected cash runway. The inclusion of forward-looking
statements should not be regarded as a representation by Evoke that
any of its plans will be achieved. Actual results may differ from
those set forth in this press release due to the risks and
uncertainties inherent in Evoke’s business, including, without
limitation: Evoke may not be able to achieve its guidance for 2024
including as a result of decreased demand for GIMOTI; Evoke’s and
EVERSANA’s ability to successfully drive market demand for GIMOTI;
Evoke’s ability to obtain additional financing as needed to support
its operations; Evoke may use its capital resources sooner than
expected; warrant holders may choose not to exercise any of the
outstanding warrants; Evoke’s dependence on third parties for the
manufacture of GIMOTI; Evoke is entirely dependent on the success
of GIMOTI; inadequate efficacy or unexpected adverse side effects
relating to GIMOTI that could result in recalls or product
liability claims; Evoke’s ability to maintain intellectual property
protection for GIMOTI; and other risks and uncertainties detailed
in Evoke’s prior press releases and in the periodic reports it
files with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Evoke
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Investor & Media Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
dboateng@dkbpartners.net
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Sep 2024 to Oct 2024
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Oct 2023 to Oct 2024